CL2024000853A1 - Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19 - Google Patents
Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19Info
- Publication number
- CL2024000853A1 CL2024000853A1 CL2024000853A CL2024000853A CL2024000853A1 CL 2024000853 A1 CL2024000853 A1 CL 2024000853A1 CL 2024000853 A CL2024000853 A CL 2024000853A CL 2024000853 A CL2024000853 A CL 2024000853A CL 2024000853 A1 CL2024000853 A1 CL 2024000853A1
- Authority
- CL
- Chile
- Prior art keywords
- pcdh19
- compositions
- methods
- treatment
- disorders related
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title 1
- 101710157832 Protocadherin-19 Proteins 0.000 abstract 5
- 102100036389 Protocadherin-19 Human genes 0.000 abstract 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248803P | 2021-09-27 | 2021-09-27 | |
| US202263333840P | 2022-04-22 | 2022-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000853A1 true CL2024000853A1 (es) | 2024-10-04 |
Family
ID=85719092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000853A CL2024000853A1 (es) | 2021-09-27 | 2024-03-22 | Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250002912A1 (https=) |
| EP (1) | EP4408532A4 (https=) |
| JP (1) | JP2024535432A (https=) |
| KR (1) | KR20240068067A (https=) |
| AU (1) | AU2022351990A1 (https=) |
| CA (1) | CA3232862A1 (https=) |
| CL (1) | CL2024000853A1 (https=) |
| CO (1) | CO2024004737A2 (https=) |
| IL (1) | IL311581A (https=) |
| MX (1) | MX2024003947A (https=) |
| PE (1) | PE20250738A1 (https=) |
| WO (1) | WO2023044545A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024206668A1 (en) * | 2023-03-31 | 2024-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic strategy for pcdh19-related encephalopathy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5624892B2 (ja) * | 2008-01-04 | 2014-11-12 | セントラル アデレード ローカル ヘルス ネットワーク インコーポレイテッド | Ｅｆｍｒ（女性に限られた癲癇及び精神遅滞）の診断方法及び治療方法 |
| EP3118326B1 (en) * | 2008-10-27 | 2020-04-29 | Sapporo Medical University | Molecular marker for cancer stem cell |
| US9562892B2 (en) * | 2012-10-02 | 2017-02-07 | New York University | Methods and agents for modulating protocadherin-18 activity |
| WO2020191233A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
-
2022
- 2022-09-27 EP EP22871200.6A patent/EP4408532A4/en active Pending
- 2022-09-27 KR KR1020247014017A patent/KR20240068067A/ko active Pending
- 2022-09-27 US US18/694,295 patent/US20250002912A1/en active Pending
- 2022-09-27 IL IL311581A patent/IL311581A/en unknown
- 2022-09-27 CA CA3232862A patent/CA3232862A1/en active Pending
- 2022-09-27 AU AU2022351990A patent/AU2022351990A1/en active Pending
- 2022-09-27 PE PE2024000576A patent/PE20250738A1/es unknown
- 2022-09-27 JP JP2024519062A patent/JP2024535432A/ja active Pending
- 2022-09-27 MX MX2024003947A patent/MX2024003947A/es unknown
- 2022-09-27 WO PCT/AU2022/051153 patent/WO2023044545A1/en not_active Ceased
-
2024
- 2024-03-22 CL CL2024000853A patent/CL2024000853A1/es unknown
- 2024-04-16 CO CONC2024/0004737A patent/CO2024004737A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4408532A1 (en) | 2024-08-07 |
| PE20250738A1 (es) | 2025-03-10 |
| MX2024003947A (es) | 2024-04-24 |
| AU2022351990A1 (en) | 2024-05-16 |
| IL311581A (en) | 2024-05-01 |
| JP2024535432A (ja) | 2024-09-30 |
| CA3232862A1 (en) | 2023-03-30 |
| EP4408532A4 (en) | 2026-01-21 |
| KR20240068067A (ko) | 2024-05-17 |
| US20250002912A1 (en) | 2025-01-02 |
| WO2023044545A1 (en) | 2023-03-30 |
| CO2024004737A2 (es) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001453A1 (es) | Compuestos y métodos para modular la expresión de angiotensinógeno. (divisional solicitud 201800899) | |
| CL2021002877A1 (es) | Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos | |
| AR106135A1 (es) | Moduladores de la expresión del sarcoma de la rata de kirsten (kras) | |
| CL2021002876A1 (es) | Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos | |
| BR112022009216A2 (pt) | Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt) | |
| CL2021003374A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| MX2015012176A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| MX2017003815A (es) | Variantes de vector de virus asociado a adeno para edicion genomica de alta eficacia y sus metodos. | |
| ECSP19014247A (es) | Formas de dosificación para tratar y prevenir trastornos del sueño | |
| AR100560A1 (es) | Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido | |
| CL2020001810A1 (es) | Oligonucleótidos antisentido para alfa-sinucleína y usos de los mismos. | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| MX2011011656A (es) | Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento. | |
| CO2021002087A2 (es) | Método para tratar la epilepsia | |
| CO2024000880A2 (es) | Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con at2r y/o señalización mediada por at2r | |
| CO2024004737A2 (es) | Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19 | |
| CO2021014024A2 (es) | Métodos para tratar la distrofia muscular con casimersin | |
| MX2024006769A (es) | Compuestos y usos de los mismos. | |
| CL2019002313A1 (es) | Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas. | |
| DOP2024000140A (es) | Composiciones y métodos para inhibir el factor b del complemento | |
| CO2023014681A2 (es) | Composiciones y métodos para inhibir la expresión del componente 3 del complemento | |
| CL2023003984A1 (es) | Composiciones del agente de arni de la cinasa de repetición 2 rica en leucina | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| BR112023000428A2 (pt) | Métodos e composições para tratar epilepsia |